Answers are grounded in this paper and cite their sources.
Background Patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more prior lines of therapy can now be treated with mechanistically distinct modalities, including CD19-directed chimeric antigen receptor (CAR) T-cell therapy, CD20×CD3 bispecific antibodies, and a Bruton tyrosine kinase inhibitor plus anti-CD20 combination. Head-to-head data are lacking, and sequencing decisions are made with limited comparative evidence. We benchmarked durability outcomes across pivotal trials using reconstructed individual patient data (rIPD) derived from published Kaplan-Meier (KM) curves. Methods KM curves and numbers-at-risk tables from pivotal prospective studies in ≥2-line R/R FL were digitized and rIPD-reconstructed using a validated algorithm: axicabtagene ciloleucel (ZUMA-5), tisagenlecleucel (ELARA), lisocabtagene maraleucel (TRANSCEND FL), mosunetuzumab, epcoritamab (EPCORE NHL-1), and zanubrutinib plus obinutuzumab versus obinutuzumab (ROSEWOOD). Prespecified durability endpoints were landmark progression-free survival (PFS) at 12 and 24 months and restricted mean survival time to 24 months (RMST24). Overall survival (OS) landmarks were summarized where follow-up permitted. ROSEWOOD served as an internal validity check using a Cox model fit to reconstructed data. Results At 24 months, landmark PFS was 65.4% (95% confidence interval (CI) 52.0-82.4) for liso-cel, 62.0% (50.2-76.6) for axi-cel, 53.8% (45.2-63.9) for zanubrutinib plus obinutuzumab, 49.3% (39.3-61.7) for mosunetuzumab, 43.7% (31.3-61.1) for epcoritamab, and 24.7% (14.9-40.9) for obinutuzumab monotherapy. Twelve-month PFS ranged from 81.8% (74.5-89.8) with liso-cel and 77.9% (69.4-87.5) with axi-cel to 61.6% (53.6-70.8), 60.4% (50.8-72.0), and 59.1% (50.5-69.1) for zanubrutinib plus obinutuzumab, mosunetuzumab, and epcoritamab, respectively; tisagenlecleucel showed 12-month PFS of 68.3% (57.2-81.6) with shorter follow-up (maximum 18.2 months). PFS RMST24 estimates were 19.5 months for liso-cel, 18.6 for axi-cel, 16.5 for zanubrutinib plus obinutuzumab, 16.2 for mosunetuzumab, 14.8 for epcoritamab, and 11.9 for obinutuzumab. OS at 24 months was high across regimens (mosunetuzumab 87.3%, liso-cel 84.6%, axi-cel 82.8%, zanubrutinib plus obinutuzumab 77.3%, and epcoritamab 67.6%). In ROSEWOOD, reconstructed data reproduced the published PFS benefit for zanubrutinib plus obinutuzumab (hazard ratio (HR) 0.48, 95% CI 0.32-0.71; p < 0.001) with a weaker OS signal (HR 0.61, 0.35-1.07; p = 0.08). Conclusions In this rIPD-based durability benchmark for ≥2-line R/R FL, the estimated landmark PFS and RMST24 values varied across regimens, with numerically higher point estimates for the CAR T-cell therapies and the zanubrutinib plus obinutuzumab combination and numerically lower estimates for the bispecific antibodies and the obinutuzumab control; CIs overlapped substantially, and 24-month OS estimates were broadly similar across regimens. Because the source trials enrolled materially different populations, these side-by-side estimates are descriptive benchmarks and should not be read as head-to-head comparisons of efficacy. Faithful internal reproduction of the randomized ROSEWOOD effect supports reconstruction fidelity. The analysis provides a transparent, durability-focused reference framework to support sequencing discussions and hypothesis generation, not comparative effectiveness conclusions.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: